Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neurodegenerative Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for p75NTR/NGFR/CD271 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NGFR ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View NGFR Products |
| Gene Delivery | NGFR Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based conformation preservation. |
View NGFR Products |
| Benchmark Ab | Anti-NGFR (Sequence of MNAC13) Recombinant positive control for assay validation. |
View NGFR Products |
| Validator | NGFR siRNA Set For target knockdown verification in cell-based assays. |
View NGFR Products |
| Related Target A | TrkA (NTRK1) High-affinity NGF receptor; essential for selectivity and off-target safety profiling. |
View NTRK1 Products |
| Related Target B | Sortilin (SORT1) Co-receptor with p75NTR for pro-neurotrophin-induced apoptosis signaling. |
View SORT1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species Cyno/Mouse evaluation | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity verified by SDS-PAGE |
| Subfamily and Off-target counter screening | Homolog panel proteins (TrkA, TrkB, TrkC) strictly verified by mass spectrometry to guarantee sequence identity |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included in the catalog for reliable assay calibration |
| False Positives in Cell Assays | Sequence-verified siRNA sets included for target-specific knockdown verification |
Live p75NTR/NGFR/CD271 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for p75NTR/NGFR/CD271 therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies (mAbs) for pain management to Antibody-Drug Conjugates (ADCs) and targeted cell therapies in oncology. As first-generation pain therapies reach clinical maturity, the next wave of R&D is targeting CD271 as a prominent cancer stem cell (CSC) marker in melanoma, squamous cell carcinoma, and triple-negative breast cancer (TNBC).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugates (ADC) | Biotech Pioneers, Academic Institutions | Melanoma, Triple-Negative Breast Cancer | Internalization Assay (Need high-purity ECD-Fc with native glycosylation) |
| Monoclonal Antibodies (mAb) | Pharmaceutical Innovators | Neuropathic Pain, Osteoarthritis | Ligand Blocking Validation (Requires functional NGF/proNGF binding assays) |
| CAR-T / Cell Therapy | Oncology Therapeutics Developers | Glioblastoma, Stem Cell-Derived Tumors | Stable Cell Line Construction (Need high-titer Lentivirus for CD271 expression) |